FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:898-904 September 16, 1993 Number 12

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Mycobacterium avium complex causes disseminated disease in as many as 15 to 40 percent of patients with human immunodeficiency virus (HIV) infection in the United States, causing fever, night sweats, weight loss, and anemia^{1,2,3,4,5,6,7}. Disseminated M. avium complex disease characteristically occurs in patients with very advanced HIV disease and peripheral-blood CD4 T-lymphocyte counts below 100 cells per cubic millimeter. Effective prevention and therapy of M. avium complex infection would probably improve the quality and duration of survival for HIV-infected persons.

During the first decade of the HIV pandemic in the United States, health care providers recognized that M. avium . . . [Full Text of this Article]

Background

Epidemiology

Clinical Manifestations

Prophylaxis

Diagnosis and Susceptibility Testing

Therapy of Disseminated M. avium Complex Disease

Recommendations

Indications for Prophylaxis

Evaluation before Prophylaxis

Prophylactic Regimens

Diagnosis of M. avium Complex Disease

Therapy for Disseminated M. avium Complex Disease

Monitoring Patients Treated for Disseminated M. avium Complex Disease

Recommendations for Children

Ongoing Studies

Source Information

This report represents the recommendations of the Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. Their publication should not be taken to imply FDA approval or approved labeling for the products and indications in question. Specifically, the terms "safe" and "effective" are not used synonymously with the FDA-defined legal standards for drug approval.
National Institutes of Health
Bethesda, MD 20892

References

Appendix

This article has been cited by other articles:

• Hammer, S. M. (2005). Clinical practice. Management of newly diagnosed HIV infection.. NEJM 353: 1702-1710 [Full Text]  
• Masur, P. b. H., Kaplan, J. E., Holmes, K. K. (2002). Guidelines for Preventing Opportunistic Infections among HIV-Infected Persons--2002: Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. ANN INTERN MED 137: 435-478 [Abstract] [Full Text]  
• Hayashi, T., Rao, S. P., Takabayashi, K., Van Uden, J. H., Kornbluth, R. S., Baird, S. M., Taylor, M. W., Carson, D. A., Catanzaro, A., Raz, E. (2001). Enhancement of Innate Immunity against Mycobacterium avium Infection by Immunostimulatory DNA Is Mediated by Indoleamine 2,3-Dioxygenase. Infect. Immun. 69: 6156-6164 [Abstract] [Full Text]  
• Ferrario, G., Gori, A., Rossi, A., Catozzi, L., Molteni, C., Marchetti, G., Bandera, A., Rossi, M. C., Esposti, A. D., Franzetti, F. (2001). PCR-Hybridization Assay for Mycobacterium avium Complex: Optimization of Detection in Peripheral Blood from Humans. J. Clin. Microbiol. 39: 1638-1643 [Abstract] [Full Text]  
• Purdy, B. D. (2000). Management and Prevention of Opportunistic Infections in the HIV-Infected Patient. Journal of Pharmacy Practice 13: 475-498 [Abstract]  
• Fattorini, L., Baldassarri, L., Li, Y.-J., Ammendolia, M. G., Fan, Y., Recchia, S., Iona, E., Orefici, G. (2000). Virulence and drug susceptibility of Mycobacterium celatum. Microbiology 146: 2733-2742 [Abstract] [Full Text]  
• Kovacs, J. A., Masur, H. (2000). Prophylaxis against Opportunistic Infections in Patients with Human Immunodeficiency Virus Infection. NEJM 342: 1416-1429 [Full Text]  
• Rossi, M. C., Gori, A., Zehender, G., Marchetti, G., Ferrario, G., De Maddalena, C., Catozzi, L., Bandera, A., Esposti, A. D., Franzetti, F. (2000). A PCR-Colorimetric Microwell Plate Hybridization Assay for Detection of Mycobacterium tuberculosis and M. avium from Culture Samples and Ziehl-Neelsen-Positive Smears. J. Clin. Microbiol. 38: 1772-1776 [Abstract] [Full Text]  
• Hackner, D., Tu, G., Weingarten, S., Mohsenifar, Z. (1999). Guidelines in Pulmonary Medicine: A 25-Year Profile. Chest 116: 1046-1062 [Abstract] [Full Text]  
• Saunders, B. M., Frank, A. A., Cooper, A. M., Orme, I. M. (1998). Role of gamma delta T Cells in Immunopathology of Pulmonary Mycobacterium avium Infection in Mice. Infect. Immun. 66: 5508-5514 [Abstract] [Full Text]  
• Fattorini, L., Xiao, Y., Mattei, M., Li, Y., Iona, E., Ricci, M. L., Thoresen, O. F., Creti, R., Orefici, G. (1998). Activities of Isoniazid Alone and in Combination with Other Drugs against Mycobacterium avium Infection in Beige Mice. Antimicrob. Agents Chemother. 42: 712-714 [Abstract] [Full Text]  
• Piersimoni, C, Nista, D, Bornigia, S, De Sio, G (1998). Evaluation of a new method for rapid drug susceptibility testing of Mycobacterium avium complex isolates by using the mycobacteria growth indicator tube [In Process Citation]. J. Clin. Microbiol. 36: 64-67 [Abstract] [Full Text]  
• (1997). Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria. Am. J. Respir. Crit. Care Med. 156: 1-25 [Full Text]  
• Havlir, D. V., Dube, M. P., Sattler, F. R., Forthal, D. N., Kemper, C. A., Dunne, M. W., Parenti, D. M., Lavelle, J. P., White, A. C., Witt, M. D., Bozzette, S. A., McCutchan, J. A., The California Collaborative Treatment Group, (1996). Prophylaxis against Disseminated Mycobacterium avium Complex with Weekly Azithromycin, Daily Rifabutin, or Both. NEJM 335: 392-398 [Abstract] [Full Text]  
• Spector, S. A., McKinley, G. F., Lalezari, J. P., Samo, T., Andruczk, R., Follansbee, S., Sparti, P. D., Havlir, D. V., Simpson, G., Buhles, W., Wong, R., Stempien, M. J., The Roche Cooperative Oral Ganciclovir Study Group, (1996). Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Persons with AIDS. NEJM 334: 1491-1497 [Abstract] [Full Text]  
• Selik, R. M., Chu, S. Y., Ward, J. W. (1995). Trends in Infectious Diseases and Cancers among Persons Dying of HIV Infection in the United States from 1987 to 1992. ANN INTERN MED 123: 933-936 [Abstract] [Full Text]  
• Advisory Group on HIV Early Intervention, Second E, (1994). Human Immunodeficiency Virus Early Intervention Physician Guidelines, Second Edition. Arch Fam Med 3: 988-1002 [Abstract]  
• Fuller, J. D., Stanfield, L. E.D., Craven, D. E. (1994). Rifabutin Prophylaxis and Uveitis. NEJM 330: 1315-1316 [Full Text]  
• Narang, P. K., Trapnell, C. B., Schoenfelder, J. R., Lavelle, J. P., Bianchine, J. R. (1994). Fluconazole and Enhanced Effect of Rifabutin Prophylaxis. NEJM 330: 1316-1317 [Full Text]  
• Frank, M. O., Graham, M. B., Wispelway, B. (1994). Rifabutin and Uveitis. NEJM 330: 868-868 [Full Text]  
• Goldschmidt, R. H., Hearst, N., Chambers, D. B., Zbrozek, A. S., von Reyn, C. F., Brown, S. T., Arbeit, R. D., Reichman, L. B., McDonald, R. J., Mangura, B. T., Nightingale, S. D., Cameron, D. W. (1994). Rifabutin Prophylaxis against Mycobacterium avium Complex Infection. NEJM 330: 436-438 [Full Text]  
• (1993). PROPHYLAXIS AGAINST M. AVIUM COMPLEX IN AIDS. JWatch General 1993: 5-5 [Full Text]